


Supplementary Figure Legends

Supplementary Figure 1. Characterization of the infused plasma and PBMC samples.

Chimpanzees A3A013, A2A015 and A3A017 were infused with plasma and PBMC from patients who mounted an SVR to interferon-based therapy as defined by a negative qualitative COBAS Amplicor HCV Test 2.0, Roche 6 months after end of therapy. The numbers of the source patients in the third column refer to a previous publication that provides clinical, virological and immunological details of their treatment courses (table 1) (8). Each plasma infusion was pooled from several plasma samples that were drawn at the indicated time points after the source patient's end of treatment. Filled circles indicate plasma samples that tested positive for HCV RNA by nested RT-PCR but negative by qualitative COBAS Amplicor HCV Test 2.0 (Roche). Open circles indicate plasma samples that tested negative by both assays.

Suppl. Figure 1



Supplementary Table 1: PCR primers

A. Primers for HCV sequence analysis of second-round PCR products *

	Sequence	Position
1.	5'-CTATCAGGCAGTACCACAAG-3'	299
2.	5'-TTCCCTGTTGCRYAGTTCAC-3'	844
3.	5'-GAAGCARTAYACYGGRCCACA-3'	1848
4.	5'-TGCTTCCGGAAGCARTCCG-3'	2096
5.	5'-GCTATCAGCAGCATCATCC-3'	2555
6.	5'-GGAGGATGATGGCATCGC-3'	2957
7.	5'-GAGCGCGYACRAAGTACGG-3'	3077
8.	5'-CCRTTGGACATAATGACC-3'	3140
9.	5'-ATGGGCGCRAGGAGTCGC-3'	3419
10.	5'-CCAARTAAAGGTCCGAGCTGCC-3'	3727
11.	5'-GGAGCGTGTAGATGGGCC-3'	4035
12.	5'-CGCCCGTGGTGTGGTCC-3'	4208
13.	5'-CACGACRAGCCGCGCTCC-3'	4378
14.	5'-CATTAGAGCGTCTGTTGC-3'	4666
15.	5'-GGTGTATTTAGGTAAGCCCG-3'	4978
16.	5'-TCTGCTTGAAYTGCTCGG-3'	5534
17.	5'-TCCCGCTGATGAARTTCC-3'	5657
18.	5'-GCCAGACTCCCTGTACCC-3'	6401
19.	5'-GGGCAYTTTACGTTGTCRGTGG-3'	6678
20.	5'-AGGGGTCCGTRAGCATGG-3'	6880
21.	5'-ATGTTYCCGCCATCTCCTGCCG-3'	7076
22.	5'-ACCGTCCTCTTYCTCCGTGG-3'	7355
23.	5'-TCAAGGGGGGGGCATGGAGG-3'	7533
24.	5'-CATCTCCTTGAGCACGTCCC-3'	7827
25.	5'-TARAGGGCCATYTTCTCGC-3'	8143
26.	5'-CTTYGCAGCTCGACAGGC-3'	8537
27.	5'-CATCAGAATCATCCTTGCCC-3'	8892
28.	5'-CTTCTGGCCGATGTCTCC-3'	9132
29.	5'-GCTGTGATATATGTCTCC-3'	9288
30.	5'-GGGGAGCAGGTAGATGCC-3'	9383

* Primers 4-30 were published in J Virol. 2007; 81:11658-11668.

B. Primers for HCV quasispecies analysis by 454 pyrosequencing

		Sequence	Position
Amplicon 1	Forward	5'-GGCTTGGGATATGATGATGAACTGGT-3'	1295
	Reverse	5'-ACCTCCCCCTCGACCTG-3'	3517
Amplicon 2	Forward	5'-ATGGCTGCATCGTGCGGAGG-3'	2781
	Reverse	5'-TCCCGCTGATGAARTTCC-3'	5655
Amplicon 3	Forward	5'-CTATGGCAAAGCCATCCC-3'	4466
	Reverse	5'-ATGTTYCCGCCATCTCCTGCCG-3'	7063
Amplicon 4	Forward	5'-CAACGCRTACACCACGGG-3'	6527
	Reverse	5'-GGGGAGCAGGTAGATGCC-3'	9368